4 Smart Money Stock Picks That Are Deeply Undervalued

By Kapitall | March 19, 2012 AAA


Written by Alexander Crawford

Do you consider yourself a value investor? If you like to look for stocks that you believe are trading below their fair value, your answer might be yes.

With value investing in mind, we ran a screen on potentially undervalued stocks. We began by screening for smart money stock picks: stocks that have seen buying attention from institutional investors over the current quarter, as well as from company insiders over the last six months.

We then screened for those that appear undervalued to target price, trading at steep discounts to even their lowest (most pessimistic) target prices. We considered the lowest target price because target prices are known to be inflated. We also only considered companies with sufficient analyst coverage, with five or more analyst target prices.

Interactive Chart: Press Play to compare changes in average analyst recommendation over the last two years for the stocks mentioned below.



Business Section: Investing Ideas
Below is the final list of stocks from this screen. These stocks have the backing of smart money investors (both institutional investors and insiders), and also appear undervalued relative to target price.

Do you think these names should be trading higher? Use this list as a starting point for your own analysis. (Click here to access free, interactive tools to analyze these ideas.)

1. American Equity Investment Life Holding Co. (NYSE:AEL): Underwrites fixed annuity and life insurance products in the United States and the District of Columbia. Of the six analysts that have set a target price on the stock, the lowest price target stands at $14.50. This implies a current upside of 17.22% from current levels around $12.37. Net institutional purchases in the current quarter at 3.8M shares, which represents about 6.77% of the company's float of 56.15M shares. Over the last six months, insiders were net buyers of 20,689 shares, which represents about 0.04% of the company's 56.15M share float.

2. OncoGenex Pharmaceuticals, Inc. (Nasdaq:OGXI): Engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Of the five analysts that have set a target price on the stock, the lowest price target stands at $20.00. This implies a current upside of 29.28% from current levels around $15.47. Net institutional purchases in the current quarter at 242.7K shares, which represents about 3.39% of the company's float of 7.16M shares. Over the last six months, insiders were net buyers of 3,000 shares, which represents about 0.04% of the company's 7.16M share float.

3. Och-Ziff Capital Management Group LLC (NYSE:OZM): A publicly owned investment manager. Of the nine analysts that have set a target price on the stock, the lowest price target stands at $11. This implies a current upside of 16.53% from current levels around $9.44. Net institutional purchases in the current quarter at 27.6M shares, which represents about 27.74% of the company's float of 99.48M shares. Over the last six months, insiders were net buyers of 702,389 shares, which represents about 0.71% of the company's 99.48M share float.

4. ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Of the five analysts that have set a target price on the stock, the lowest price target stands at $6. This implies a current upside of 16.50% from current levels around $5.15. Net institutional purchases in the current quarter at 11.5M shares, which represents about 25.04% of the company's float of 45.93M shares. Over the last six months, insiders were net buyers of 1,351,460 shares, which represents about 2.94% of the company's 45.93M share float.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Kapitall's Alexander Crawford does not own any of the shares mentioned above. Target price and insider data sourced from Yahoo! Finance, institutional data sourced from Fidelity.

comments powered by Disqus
Related Analysis
  1. India Remains An Emerging Market Bright Spot
    Stock Analysis

    India Remains An Emerging Market Bright Spot

  2. Still More Gains Ahead For Semiconductor Makers
    Stock Analysis

    Still More Gains Ahead For Semiconductor Makers

  3. Unconventional Drilling Still Has Room To Boom
    Stock Analysis

    Unconventional Drilling Still Has Room To Boom

  4. Finding An Alternative With Currency ETFs
    Stock Analysis

    Finding An Alternative With Currency ETFs

  5. Commodities: Has Their Time Come Again?
    Stock Analysis

    Commodities: Has Their Time Come Again?

Trading Center